Foresee Pharmaceuticals to Present Phase 3 KATANA Studies of Novel Prostate Cancer Treatment at ASCO-GU 2025
核心洞察
Foresee Pharmaceuticals (搜索) will present data from their Phase 3 KATANA (搜索) studies evaluating FP-014, a novel triptorelin mesylate (搜索) injection for advanced prostate cancer (搜索), at the 2025 ASCO-GU (搜索) Symposium.
The studies investigate two formulations: an 11.25 mg quarterly injection and a 22.5 mg semi-annual injection, aiming to become the first ready-to-use triptorelin long-acting injectable.
The presentation highlights Foresee's SIF-LAI technology platform and its potential to develop best-in-class long-acting injectables for cancer treatment.
Foresee Pharmaceuticals (搜索) (TPEx: 6576) has secured a presentation slot at the upcoming American Society of Clinical Oncology Genitourinary (ASCO-GU (搜索)) Cancers Symposium, scheduled for February 13-15, 2025, in San Francisco. The presentation will showcase their Phase 3 KATANA (搜索) studies investigating FP-014, a novel treatment for advanced prostate cancer (搜索).
The clinical program evaluates two formulations of triptorelin mesylate (搜索) injection: an 11.25 mg dose administered every three months and a 22.5 mg dose given every six months. These global, open-label, single-arm studies aim to assess the efficacy, safety, and pharmacokinetics of both formulations in patients with advanced prostate cancer (搜索).
Innovation in Drug Delivery
Building on the success of their CAMCEVI® product, Foresee's FP-014 leverages their proprietary SIF-LAI (Stabilized Injectable Formulation for Long-Acting Injectables) technology. The development positions FP-014 to potentially become the only available ready-to-use triptorelin long-acting injectable in the market.
Dr. Yisheng Lee, Chief Medical Officer at Foresee, emphasized the significance of the presentation: "This prestigious event brings together leading urology, oncology, and cancer research experts to discuss the latest advancements and findings related to prostate cancer (搜索). The accepted abstract presents our differentiated FP-014 Phase 3 clinical program and highlights our broad efforts in developing new treatment modalities."
Technical Innovation and Market Potential
Dr. Yuhua Li, Chief Technology Officer at Foresee, highlighted the broader implications of their technology platform: "This acceptance demonstrates the success of Foresee's pioneering SIF-LAI technology across several product types and indications, further highlighting the broad potential of this technology in developing best-in-class ready-to-use LAI's."
The company's leadership sees significant market potential for FP-014. Dr. Ben Chien, Foresee's Chairman and CEO, stated, "We are excited to initiate our studies later this year, as we see a remarkable opportunity to capture a significant share of the triptorelin market around the world in view of FP-014's best-in-class profile."
The abstract presentation details (Abstract Number: TPS284) is scheduled for Thursday, February 13, 2025, from 11:25 AM to 12:45 PM PT in the Trials in Progress Poster Session A: Prostate Cancer (搜索) at the Moscone Convention Center West's Level 1, West Hall.